Great call on RPC (.90) from biomedreports. They did a story on them yesterday in the mid .30's and today they are at .90!
Message in reply to:
RPC
Written by M.E.Garza
Wednesday, 07 April 2010 00:00
We may have found a bottom play that is primed for gains in both the short and long term.
Radient Pharmaceuticals Corporation (AMEX: RPC), is starting to break out and if it is able to break-through some resistance at around $.38 cents today, then it is very likely that this stock will run, especially given how the shares of the company are structured.
We have a special report and interview with the CEO of the company that will be press-released and run on the site on Thursday. The company has an FDA approved cancer dignostics test that reportedly changes the whole dynamic of cancer detection and the CEO will explain the full implications of it during the interview.
Keep in mind that this is an AMEX stock and that late last month, Radient received notice from the New York Stock Exchange Amex indicating that it had accepted the Company's business plan of compliance, and granted RPC an extension until June 23, 2010 to regain compliance with the Exchange's continued listing standards. The company has been underogoing some debt restructuring and all indications are the price will go higher from here regardless of today or tomorrow's price action.
"We've had a transition here where we've really had to redefine ourselves and I think that was critical to a long term success," explains Douglas C. MacLellan, CEO of Radient Pharmaceuticals. "We believe the diagnostics business is our best and strongest opportunity and we're now fully focused on that with the idea that we will monetize the value of the Chinese pharmaceutical company (which they purchased as a money making asset and that itself is worth far more than the current price of the stock). We can decide to either spin it (the Chinese pharma company) off as it's own public company or we can decide to sell it at a slight discount or sell it for a combination of cash and stock in another public company. "
Sources also tell us that there is at least one publicly traded company that is interested in purchasing that far-east pharma property from Radient.
Take a look at the chart below and take a close look at the key level of resistance (around $.38) which is very close to being broken now. Investors know a bargain when they see one and in my opinion, this one is just starting to run:
BioMed Report
Sheff's Station...All Aboard...Sign Up Here!
AI
